Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index; 54 of the 60 sources its claims cite were checked for support.

The effect of Abi3 locus deletion on the progression of Alzheimer’s disease-related pathologies

Open access
Karahan, Hande, Smith, Daniel C., Kim, Byungwook, McCord, Brianne, Mantor, Jordan, John, Sutha K., Al-Amin, Md Mamun, Dabin, Luke C., Kim, Jungsu · 2023 · Frontiers in Immunology

Abstract

Human genetics studies of Alzheimer’s disease (AD) have identified the ABI3 gene as a candidate risk gene for AD. Because ABI3 is highly expressed in microglia, the brain’s immune cells, it was suggested that ABI3 might impact AD pathogenesis by regulating the immune response. Recent studies suggest that microglia have multifaceted roles in AD. Their immune response and phagocytosis functions can have beneficial effects in the early stages of AD by clearing up amyloid-beta (Aβ) plaques. However, they can be harmful at later stages due to their continuous inflammatory response. Therefore, it is important to understand the role of genes in microglia functions and their impact on AD pathologies along the progression of the disease. To determine the role of ABI3 at the early stage of amyloid pathology, we crossed Abi3 knock-out mice with the 5XFAD Aβ-amyloidosis mouse model and aged them until 4.5-month-old. Here, we demonstrate that deletion of the Abi3 locus increased Aβ plaque deposition, while there was no significant change in microgliosis and astrogliosis. Transcriptomic analysis indicates alterations in the expression of immune genes, such as Tyrobp, Fcer1g, and C1qa. In addition to the transcriptomic changes, we found elevated cytokine protein levels in Abi3 knock-out mouse brains, strengthening the role of ABI3 in neuroinflammation. These findings suggest that loss of ABI3 function may exacerbate AD progression by increasing Aβ accumulation and inflammation starting from earlier stages of the pathology.

Overview

CoChat Summary

TL;DR

In 4.5-month-old 5XFAD mice, deletion of the Abi3 locus increased insoluble Aβ40 and fibrillar plaque load without altering overall microgliosis or astrogliosis, while altering immune gene expression and cytokine levels. These findings suggest that loss of ABI3 function may exacerbate early AD-related amyloid and inflammatory pathology.

Key findings

  • Insoluble guanidine-extracted Aβ40 was increased 1.6-fold in Abi3-/- cortices, and PBS-soluble Aβ40 was decreased by 61%; RIPA-soluble Aβ42 was significantly increased, while PBS-soluble Aβ42 was significantly decreased with a smaller effect size.
  • X34+ fibrillar plaque area and plaque number were significantly increased in Abi3-/- mice, but IBA1+ microglial area and GFAP+ astrocyte area were not significantly different; more GFAP+ cells colocalized with plaques in Abi3-/- mice.
  • Transcriptomic analysis found Ctss, Fcer1g, Tyrobp, C1qa, and Cyba as the most significantly upregulated genes and Ap3b2 as the most downregulated; 32 DEGs were shared between young and old cohorts, with 53 young-specific and 64 old-specific DEGs.
  • In PBS-soluble cortical fractions, IL-33 and CCL2 were significantly decreased, while CXCL10 and CCL3 were significantly increased; CXCL2 did not differ. In RIPA-soluble fractions, CXCL10, CCL3, and CCL2 were significantly increased.

Methods

  • Abi3 knock-out mice were crossed with 5XFAD mice to generate 5XFAD;Abi3+/+ and 5XFAD;Abi3-/- mice; female 4.5-month-old mice were used.
  • Cortical tissue was analyzed by Western blot, MSD electrochemiluminescence for Aβ40/Aβ42 and cytokines, X34/IBA1/GFAP immunohistochemistry, and NanoString nCounter Mouse AD panel transcriptomics.
  • Statistical comparisons used unpaired two-tailed t-tests and Pearson correlations; sample sizes included n=13–16 for Aβ assays, n=9–10 for histology, n=6/genotype for NanoString, and n=14–15 for cytokines.

Limitations

  • The paper does not include a dedicated limitations section.
  • Evident from the text: experiments used only female 4.5-month-old 5XFAD mice, so findings may not generalize to males, other ages, or other AD models; the paper itself notes conflicting results in TgCRND8 mice and attributes differences partly to distinct familial AD mutations.
  • Evident from the text: transcriptomic profiling used the nCounter Mouse AD panel covering 760 genes rather than whole-transcriptome sequencing, and the mechanism linking Abi3 deletion to increased Aβ remains indirect because Aβ production/degradation proteins did not differ and microglial migration impairment was proposed from prior work.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fimmu.2023.1102530

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Aβ accumulation increases in Abi3-/- mice. (A–C) Sequential protein extraction was performed on the cortical tissues with PBS, RIPA, and Guanidine buffer. The levels of Aβ40 were measured in the (A) guanidine, (B) RIPA, and (C) PBS-soluble fractions of 5XFAD mouse cortices using an MSD electrochemiluminescence assay. (D–F) The levels of Aβ42 were measured in the (D) guanidine, (E) RIPA, and (F) PBS-soluble fractions of 5XFAD mouse cortices (n=13-16). Data represent mean ± SEM. Unpaired two-tailed t-test; *p < 0.05, **p < 0.01. (G, H) A significant correlation was observed between (G) Guanidine-soluble Aβ40 and Aβ42, and (H) PBS-soluble Aβ40 and Aβ42 levels. (I, J) Correlation analyses were performed between Guanidine-soluble and PBS-soluble fractions for (I) Aβ40 and (J) Aβ42 levels. Pearson’s correlation analysis; *p < 0.05, ***p < 0.001, ****p < 0.0001.
Figure 1 Aβ accumulation increases in Abi3-/- mice. (A–C) Sequential protein extraction was performed on the cortical tissues with PBS, RIPA, and Guanidine buffer. The levels of Aβ40 were measured in the (A) guanidine, (B) RIPA, and (C) PBS-soluble fractions of 5XFAD mouse cortices using an MSD electrochemiluminescence assay. (D–F) The levels of Aβ42 were measured in the (D) guanidine, (E) RIPA, and (F) PBS-soluble fractions of 5XFAD mouse cortices (n=13-16). Data represent mean ± SEM. Unpaired two-tailed t-test; *p < 0.05, **p < 0.01. (G, H) A significant correlation was observed between (G) Guanidine-soluble Aβ40 and Aβ42, and (H) PBS-soluble Aβ40 and Aβ42 levels. (I, J) Correlation analyses were performed between Guanidine-soluble and PBS-soluble fractions for (I) Aβ40 and (J) Aβ42 levels. Pearson’s correlation analysis; *p < 0.05, ***p < 0.001, ****p < 0.0001.CC BY · PubMed Central
Figure 2 Deletion of the Abi3 gene locus increases amyloid plaques without altering gliosis in 5XFAD mice. (A) Representative images showing coronal brain sections from 4.5-month-old Abi3+/+ and Abi3-/- mice stained with X34 dye, which detects fibrillar plaques (Scale bar; 250 μm). Black stain indicates X34+ amyloid plaques. (B) Quantification of X34+ fibrillar plaque area and (C) the number of plaques in mouse cortices. (D) Representative images showing coronal brain sections stained with X34 dye and the microglial marker IBA1 antibody (Scale bar; 50 μm). (E) Quantification of IBA1+ area and (F) the area covered by IBA1 staining colocalized with X34+ plaques. (G) Representative images showing coronal brain sections stained with X34 dye and the astrocyte marker GFAP antibody (Scale bar; 50 μm). (H) The percent of the area covered by GFAP staining was quantified in the cortices of mice. (I) Quantification of GFAP+ area colocalized with X34+ plaques. Data represent mean ± SEM (n=9-10). Unpaired two-tailed t-test; *p < 0.05, **p < 0.01. See also Supplementary Figure 2 .
Figure 2 Deletion of the Abi3 gene locus increases amyloid plaques without altering gliosis in 5XFAD mice. (A) Representative images showing coronal brain sections from 4.5-month-old Abi3+/+ and Abi3-/- mice stained with X34 dye, which detects fibrillar plaques (Scale bar; 250 μm). Black stain indicates X34+ amyloid plaques. (B) Quantification of X34+ fibrillar plaque area and (C) the number of plaques in mouse cortices. (D) Representative images showing coronal brain sections stained with X34 dye and the microglial marker IBA1 antibody (Scale bar; 50 μm). (E) Quantification of IBA1+ area and (F) the area covered by IBA1 staining colocalized with X34+ plaques. (G) Representative images showing coronal brain sections stained with X34 dye and the astrocyte marker GFAP antibody (Scale bar; 50 μm). (H) The percent of the area covered by GFAP staining was quantified in the cortices of mice. (I) Quantification of GFAP+ area colocalized with X34+ plaques. Data represent mean ± SEM (n=9-10). Unpaired two-tailed t-test; *p < 0.05, **p < 0.01. See also Supplementary Figure 2 .CC BY · PubMed Central
Figure 3 Deletion of the Abi3 locus alters immune response genes in 5XFAD mice. (A, B) Differentially expressed genes (DEGs) were identified in the cortices of 4.5-month-old Abi3-/- mice compared to Abi3+/+ mice using the nCounter NanoString mouse AD panel (n=6/genotype). (A) The Volcano plot demonstrates the fold change (x-axis) and statistical significance level expressed as the −log10 P value (y-axis). The red dots represent genes significantly upregulated by more than 1.5-fold in Abi3-/- mice compared to Abi3+/+ mice. (B) The heatmap demonstrates the gene expression levels of DEGs altered by more than 1.5-fold in Abi3-/- mice compared to Abi3+/+ mice after z-score transformation. Upregulation is shown in purple and downregulation is in pink color. Each column represents each mouse. (C) Gene ontology (GO) and (D) Network analyses were performed for DEGs using the MetaCore™ software. (E) Pathway analysis was performed using MetaCore™. Upregulated genes in our dataset are shown with red circles and downregulated genes are shown with blue circles in the pathmap. Green arrows between nodes represent activation, while grey arrows represent interaction with no specific direction of effect. See also Supplementary Tables 1 - 3 and Supplementary Figure 3 .
Figure 3 Deletion of the Abi3 locus alters immune response genes in 5XFAD mice. (A, B) Differentially expressed genes (DEGs) were identified in the cortices of 4.5-month-old Abi3-/- mice compared to Abi3+/+ mice using the nCounter NanoString mouse AD panel (n=6/genotype). (A) The Volcano plot demonstrates the fold change (x-axis) and statistical significance level expressed as the −log10 P value (y-axis). The red dots represent genes significantly upregulated by more than 1.5-fold in Abi3-/- mice compared to Abi3+/+ mice. (B) The heatmap demonstrates the gene expression levels of DEGs altered by more than 1.5-fold in Abi3-/- mice compared to Abi3+/+ mice after z-score transformation. Upregulation is shown in purple and downregulation is in pink color. Each column represents each mouse. (C) Gene ontology (GO) and (D) Network analyses were performed for DEGs using the MetaCore™ software. (E) Pathway analysis was performed using MetaCore™. Upregulated genes in our dataset are shown with red circles and downregulated genes are shown with blue circles in the pathmap. Green arrows between nodes represent activation, while grey arrows represent interaction with no specific direction of effect. See also Supplementary Tables 1 - 3 and Supplementary Figure 3 .CC BY · PubMed Central
Figure 4 Deletion of the Abi3 locus alters the levels of secreted cytokines in 5XFAD mice. Protein levels of cytokines were measured in the PBS fraction of 4.5-month-old 5XFAD mouse cortices using the MSD mouse cytokine panel. (A) IL-33, (B) CXCL10, and (C) CCL3 were significantly increased, whereas (D) CCL2 was decreased in Abi3-/- mice compared to Abi3+/+ mice. (E) CXCL2 levels did not change between the genotypes. All data were normalized by total protein level and given as mean ± SEM (n=14-15). Unpaired two-tailed t-test, *p < 0.05, **p < 0.01.
Figure 4 Deletion of the Abi3 locus alters the levels of secreted cytokines in 5XFAD mice. Protein levels of cytokines were measured in the PBS fraction of 4.5-month-old 5XFAD mouse cortices using the MSD mouse cytokine panel. (A) IL-33, (B) CXCL10, and (C) CCL3 were significantly increased, whereas (D) CCL2 was decreased in Abi3-/- mice compared to Abi3+/+ mice. (E) CXCL2 levels did not change between the genotypes. All data were normalized by total protein level and given as mean ± SEM (n=14-15). Unpaired two-tailed t-test, *p < 0.05, **p < 0.01.CC BY · PubMed Central

Verification

Claims the paper makes

32 Valid · 0 Not valid · 1 Not checked · 76 Own results and interpretations

70 more claims · 9 with their cited sources checked

Create a free account to see all 109 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 14
  • It may state two separate claims as one. 26

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 59 references

Cited by

See all 20

Metadata

Authors
Karahan, H., Smith, D. C., Kim, B., McCord, B., Mantor, J., John, S. K., Al-Amin, M. M., Dabin, L. C., & Kim, J.
Affiliations
  • Indiana University School of Medicine (US)
  • Indiana University Indianapolis (US)
Corresponding author
Kim, Jungsu
Venue
Frontiers in Immunology
Published
2023-02-21
Volume
14
Pages
1102530-1102530
ISSN
1664-3224 (ISSN-L)
OpenAlex
W4321459283
Cited by
20
References
59
Citations by year
2026: 6 · 2025: 8 · 2024: 5 · 2023: 1
FWCI
3.53
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Institutes of Health (R01AG071281, RF1AG074543, R01AG077829, R21AG072738)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
ABI3, Alzheimer's disease, amyloid plaques, microglia, neuroinflammation, 5xFAD mice, amyloidosis, microglial activation, astrocyte activation, cytokines, immune gene expression, C1QA, FCER1G, TYROBP, disease progression
MeSH terms
Alzheimer Disease, Amyloidosis, Animals, Brain, Humans, Amyloid beta-Peptides, Microglia, Mice, Knockout, Adaptor Proteins, Signal Transducing, Mice, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-17, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-17 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The effect of Abi3 locus deletion on the progression of Alzheimer’s disease-related pathologies. https://app.cochat.ai/papers/10.3389/fimmu.2023.1102530
The paper
Karahan, H., Smith, D. C., Kim, B., McCord, B., Mantor, J., John, S. K., Al-Amin, M. M., Dabin, L. C., & Kim, J. (2023). The effect of Abi3 locus deletion on the progression of Alzheimer’s disease-related pathologies. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2023.1102530

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.